Scientists map new pathways to treat rosacea beyond skin creams
Researchers have identified how nerve signaling, blood vessel dysfunction, and immune activation work together to cause rosacea, opening doors to treatments targeting the root causes rather than just symptoms. The finding matters because rosacea affects millions globally and often triggers anxiety and depression—expanding treatment options could unlock a significant market opportunity for pharmaceutical companies.
Originaltitel: Therapeutic progress in rosacea: targeting the neuro-vascular-immune triad
Rosaceabehandling närmar sig ett paradigmskifte genom att adressera tre samverkande mekanismer: nervös-, vaskulär- och immunrespons. Ett kinesiskt forskningssamarbete mellan Nanjing Medical University och Falun Hospital kartlägger nya terapeutiska vägar bortom klassiska topikala läkemedel. Gammabufyrolakton-derivat, antidepressiva, anti-CGRP-ämnen och transkutan vagus nervstimulering utgör framtidskandidater. Även botulinumtoxin typ A och betablockerare visar effekt genom neuromodulerande vägar. Mekanismerna är väl kartlagda, men kliniken saknar randomiserade stora prövningar — dosering och behandlingslängd återstår opreciserad. För inköpschefer och sjukhusledning signalerar detta en övergångsfas från symptomatisk mot patogenetisk behandling. Tidshorisont till marknadsgodkännande för nya substanser uppskattas till 3–5 år. Investerare bör följa CGRP-segmentet och neuromodulerande enheter närmare.
Rosacea is a chronic inflammatory dermatological condition predominantly affecting the facial region. Clinically, rosacea is characterized by paroxysmal flushing, persistent erythema, telangiectasia, papules, pustules, and ocular symptoms. Severe rosacea cases are frequently complicated by anxiety, depression, and sleep disturbances, imposing a heavy psychosocial burden and markedly impairing the quality of life of the patients. Abnormal activation of the neuro-vascular-immune triad has been reported as a crucial pathological mechanism of rosacea. Moreover, dysregulation within the central nervous system might exacerbate disease progression by modulating peripheral nerve activity and neuroendocrine homeostasis. In this review, we summarize the latest advancements in rosacea treatments targeting the neuro-vascular-immune triad, including γ-aminobutyric acid derivatives, antidepressants, anti-calcitonin gene-related peptide agents, physical neuromodulation (transcutaneous auricular vagus nerve and repetitive transcranial magnetic stimulations), botulinum toxin type A, and β-blockers. We provide a comprehensive analysis of their molecular mechanisms, clinical efficacy, and current limitations. While such therapies could specifically regulate different stages of the pathway, their evidence lacks large-scale randomized controlled trials and clarity regarding optimal dosing regimens and treatment durations. Future studies should strengthen basic investigations and clinical translation, explore combined therapeutic strategies, as well as develop personalized therapeutic strategies for the long-term effective control of rosacea.